Tourmaline Bio, Inc. - Utang jangka cendhak perusahaan TRML

Diversifying the antibody portfolio across various pathologies minimizes trial failure risks, as reflected in the price action on GURU.Markets, where the indicator stands at 0.00. Tourmaline Bio, Inc. (TRML) bases its business on developing treatments for autoimmune disorders with unmet therapeutic needs. Currently, the startup is deploying its existing capital toward costly clinical trials, ensuring autonomous funding for the development of its innovative products.

This indicator is calculated as the aggregate of all liabilities with a maturity of up to one year. This metric determines current solvency and the risk of a liquidity shortage. For the emerging biotech Tourmaline Bio, Inc. (TRML), debt control confirms the team's financial stability during the development of immune drugs. The trend in total short-term debt allows for an assessment of the company's actual margin of safety. Analyzing the curve helps investors recognize the threat of a cash gap in a timely manner.